Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supply Side East In Brief

This article was originally published in The Tan Sheet

Executive Summary

DSM green tea: DSM Nutritional Products announces U.S. launch of Teavigo green tea extract at Supply Side East Tradeshow & Conference in Baltimore, Md. May 6. The ingredient is the first pure epigallocatechin gallate (EGCG) product that is caffeine free and contains 94% ECGC - a higher concentration than competing green tea products, firm says. DSM is working to obtain status as generally recognized as safe for the ingredient by the end of 2005. The substance's U.S. launch coincides with the completion of a study showing its efficacy in preventing weight gain in obese mice. The study was presented at the scientific sessions of the American Society of Pharmacology & Experimental Therapeutics at Experimental Biology in Washington, D.C. April 18. DSM currently is organizing a study in humans on the ingredient's efficacy...

You may also be interested in...



DSM Expands Vitamin Presence In China With Roche Shanghai Purchase

DSM is bolstering its nutritionals business with the purchase of additional equity in Roche vitamins

DSM Expands Vitamin Presence In China With Roche Shanghai Purchase

DSM is bolstering its nutritionals business with the purchase of additional equity in Roche vitamins

DSM Expands Vitamin Presence In China With Roche Shanghai Purchase

DSM is bolstering its nutritionals business with the purchase of additional equity in Roche vitamins

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel